Drugs / CHF6297
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02815488 | Jan 2016 → Mar 2019 | chronic obstructive pulmonary disease | Chiesi Farmaceutici S.p.A. | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CHF6297 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02815488 ↗ |
| Action | Inhibit | “CHF6297 is a potent and selective inhibitor of human MAP kinase p38” NCT02815488 ↗ |